A new treatment for advanced skin cancer could prevent the disease from worsening for a year in some patients, research has suggested.
Pharmaceutical firm Roche has been trialling using a new drug in combination with an existing treatment for the disease.
Melanoma is the fifth most common cancer in the UK with about 13,000 new cases diagnosed each year.
There are about 2,000 deaths a year as a result of the disease and, unusually for cancer, more than a quarter of people diagnosed with it are under the age of 50.
Skin cancer rates are also rising and have increased by almost a third in Scotland between 2003 and 2013, when there were 1,172 diagnoses of melanoma north of the border.
Trials using the new drug cobimetinib, which Roche believes could enhance anti-tumour activity, together with the existing treatment vemurafenib, have helped those with previously untreated advanced melanoma - with patients typically not seeing their disease worsen for a year.
The experimental treatment can halt the progression of the disease for longer than the current standard treatment, according to Roche.
Gillian Nuttall, founder of Melanoma UK, said: "These new research findings represent a significant step forward.
"Preventing disease progression is an absolute priority to improving patients' quality of life and new treatment advances such as this are key to tackling this devastating disease."
Dr James Larkin, lead investigator for the research, today presented its findings to the American Society of Clinical Oncology.
Dr Larkin, a consultant medical oncologist at leading cancer care centre The Royal Marsden Hospital, said: "The results of the coBRIM study reinforce that our continued attention and focus on this disease is providing the clinical advances we need to improve the quality of life and survival for people with melanoma across the UK.
"Targeting two parts of this cellular pathway, by adding cobimetinib in combination with vemurafenib, sees patients live on average for over a year without their disease progressing - an important advance in melanoma, a significantly life-limiting cancer."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article